TLX
Income statement / Annual
Last year (2024), Telix Pharmaceuticals Limited's total revenue was $783.21 M,
an increase of 55.85% from the previous year.
In 2024, Telix Pharmaceuticals Limited's net income was $49.92 M.
See Telix Pharmaceuticals Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$783.21 M |
$502.55 M |
$155.98 M |
$4.90 M |
$4.68 M |
$24.19 M |
$20.44 M |
$31.77 M |
$29.40 M |
$32.32 M |
| Cost of Revenue |
$273.53 M
|
$188.16 M
|
$61.56 M
|
$2.55 M
|
$2.02 M
|
$18.53 M
|
$16.08 M
|
$53.84 M
|
$21.35 M
|
$24.86 M
|
| Gross Profit |
$509.68 M
|
$314.39 M
|
$94.43 M
|
$2.35 M
|
$2.66 M
|
$5.66 M
|
$4.36 M
|
-$22.07 M
|
$8.05 M
|
$7.46 M
|
| Gross Profit Ratio |
0.65
|
0.63
|
0.61
|
0.48
|
0.57
|
0.23
|
0.21
|
-0.69
|
0.27
|
0.23
|
| Research and Development Expenses |
$194.64 M
|
$128.54 M
|
$57.86 M
|
$34.14 M
|
$23.09 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$117.66 M
|
$78.99 M
|
$77.32 M
|
$34.92 M
|
$18.01 M
|
$5.87 M
|
$10.10 M
|
-$8.55 M
|
$9.19 M
|
$10.41 M
|
| Selling & Marketing Expenses |
$115.20 M
|
$54.87 M
|
$16.19 M
|
$5.89 M
|
$1.20 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$232.86 M
|
$133.85 M
|
$93.50 M
|
$40.81 M
|
$19.21 M
|
$5.87 M
|
$10.10 M
|
-$8.55 M
|
$9.19 M
|
$10.41 M
|
| Other Expenses |
$54,000.00
|
$35.85 M
|
$3.09 M
|
$23.55 M
|
$2.96 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$427.55 M
|
$308.50 M
|
$189.44 M
|
$101.15 M
|
$52.44 M
|
$5.87 M
|
$10.10 M
|
-$8.55 M
|
$9.19 M
|
$10.41 M
|
| Cost And Expenses |
$701.08 M
|
$486.71 M
|
$251.00 M
|
$103.70 M
|
$54.47 M
|
$24.39 M
|
$26.18 M
|
$45.29 M
|
$30.54 M
|
$35.27 M
|
| Interest Income |
$10.86 M
|
$1.02 M
|
$1,000.00
|
$0.00
|
$67,000.00
|
$139,141.80
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$36.49 M
|
$13.14 M
|
$6.42 M
|
$5.22 M
|
$1.18 M
|
$715,586.40
|
$1.33 M
|
$920,206.82
|
$518,962.40
|
$419,640.75
|
| Depreciation & Amortization |
$0.00
|
$6.74 M
|
$228,485.00
|
$236,558.00
|
$206,297.00
|
$1.61 M
|
$1.67 M
|
$1.69 M
|
$2.42 M
|
$3.39 M
|
| EBITDA |
$92.55 M |
$22.97 M |
-$86.83 M |
-$70.07 M |
-$41.88 M |
$397,548.00 |
-$3.59 M |
-$1.09 M |
$2.00 M |
$1.44 M |
| EBITDA Ratio |
0.12
|
0.05
|
-0.56
|
-14.31
|
-8.95
|
0.02
|
-0.18
|
-0.03
|
0.07
|
0.04
|
| Operating Income Ratio |
0.1
|
0.03
|
-0.59
|
-15.36
|
-9.99
|
-0.05
|
-0.26
|
-0.09
|
-0.01
|
-0.06
|
| Total Other Income/Expenses Net |
-$26.07 M
|
-$12.75 M
|
-$3.61 M
|
-$5.22 M
|
$1.85 M
|
-$715,586.40
|
-$1.33 M
|
-$1.90 M
|
-$518,962.40
|
-$419,640.75
|
| Income Before Tax |
$56.06 M
|
$3.09 M
|
-$98.62 M
|
-$80.47 M
|
-$47.94 M
|
-$1.93 M
|
-$6.60 M
|
-$4.68 M
|
-$939,405.20
|
-$2.37 M
|
| Income Before Tax Ratio |
0.07
|
0.01
|
-0.63
|
-16.43
|
-10.24
|
-0.08
|
-0.32
|
-0.15
|
-0.03
|
-0.07
|
| Income Tax Expense |
$6.14 M
|
-$2.12 M
|
$5.46 M
|
$45,000.00
|
-$3.05 M
|
$58,212.39
|
$66,716.50
|
$920,206.82
|
-$91,581.60
|
$31,541.63
|
| Net Income |
$49.92 M
|
$5.21 M
|
-$104.08 M
|
-$80.51 M
|
-$44.89 M
|
-$1.99 M
|
-$6.66 M
|
-$5.60 M
|
-$847,823.60
|
-$2.40 M
|
| Net Income Ratio |
0.06
|
0.01
|
-0.67
|
-16.44
|
-9.59
|
-0.08
|
-0.33
|
-0.18
|
-0.03
|
-0.07
|
| EPS |
0 |
0 |
0 |
0 |
0 |
-0.17038 |
-2.56 |
-0.4939 |
-0.0742366 |
-0.20571 |
| EPS Diluted |
0 |
0 |
0 |
0 |
0 |
-0.17038 |
-2.56 |
-3.26 |
-0.49954 |
-1.43 |
| Weighted Average Shares Out |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$11.42 M
|
$2.60 M
|
$11.42 M
|
$11.42 M
|
$11.42 M
|
| Weighted Average Shares Out Diluted |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$11.42 M
|
$2.60 M
|
$1.71 M
|
$1.71 M
|
$1.67 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
